How Acelryin Achieved One of Biotech's Largest IPO's to Date

Samson Amore

Samson Amore is a reporter for dot.LA. He holds a degree in journalism from Emerson College. Send tips or pitches to samsonamore@dot.la and find him on Twitter @Samsonamore.

How Acelryin Achieved One of Biotech's Largest IPO's to Date
Evan Xie

Agoura Hills-based clinical biopharmaceutical company Acelyrin went public on the NASDAQ markets May 5, securing one of Los Angeles’ most valuable initial public offerings in two years.

The IPO priced Acelyrin’s 34.5 million shares at $18 apiece, netting the company $621 million. It is now trading under the symbol SLRN.


The listing was not only the largest in Los Angeles, but also nationwide – second only to Irvine-based electric automaker Rivian’s massive $12 billion IPO in November 2021. It’s also larger than any of the biotech IPOs that happened last year.

Acelyrin was founded by CEO Shao-Lee Lin in July 2020. Instead of creating its own drugs, Acelyrin is in the business of acquiring, developing and commercializing medicines.

Its main product is a drug called Izokibep which is currently in clinical trials. According to Acelyrin, Izokibep can treat a number of issues including psoriatic arthritis (arthritis that people with the autoimmune disease psoriasis sometimes develop), uveitis (a condition in which the middle layer of the eyeball gets inflamed), and hidradenitis suppurativa, a skin issue that causes small painful lumps to grow underneath skin.

Lin wasn’t available to comment, but told the Wall Street Journal about the IPO timing, “it seemed like the right time to approach the public markets and present our story.” Lin also said she thought Acelylrin’s stable of drugs was strong enough that it could successfully weather the public markets.

While the U.S.’ IPO market remains pretty stagnant, biotechnology companies are showing more activity than other sectors. Startups across the board are both seeing fewer exits and less value from them, and both investors and founders are extra cautious about sending startups out to rickety public markets.

Morgan Stanley recently predicted that the healthcare industry – specifically, pharmaceutical companies looking to acquire new biotech businesses and their patents – are poised to weather the mild recession coming out of the global COVID-19 pandemic. In 2022 only 22 biotech companies went public, compared to 110 in 2021, according to NASDAQ.

It remains to be seen if this IPO is indicative of a larger trend of biotech firms embracing public markets again. But Acelyrin’s public debut is notable because it actually upsized its offering because of investor and underwriter demand, adding roughly 50% more shares than the original 20.6 million.

Now valued at $2.1 billion, Acelyrin was quickly scooping up venture and private equity funding prior to the IPO. It raised roughly $558 million before going public, including in Series B and C rounds worth more than $100 million in 2021 and 2022. One of Acelyrin’s backers is Westlake Village BioPartners, a repeat investor based on the border of LA and Ventura Counties.

In its first day of trading last Friday, Acelyrin saw its share price climb 30%. As of this writing, it’s now up about 1.2% to nearly $25 per share.

https://twitter.com/samsonamore
samsonamore@dot.la

Subscribe to our newsletter to catch every headline.

From AI to Layoffs, Here's Why College Grads No Longer Want Tech Jobs

Lon Harris
Lon Harris is a contributor to dot.LA. His work has also appeared on ScreenJunkies, RottenTomatoes and Inside Streaming.
From AI to Layoffs, Here's Why College Grads No Longer Want Tech Jobs
Evan Xie

A new report in Bloomberg suggests that younger workers and college graduates are moving away from tech as the preferred industry in which to embark on their careers. While big tech companies and startups once promised skilled young workers not just the opportunity to develop cutting-edge, exciting products, but also perks and – for the most talented and ambitious newcomers – a relatively reliable path to wealth. (Who could forget the tales of overnight Facebook millionaires that fueled the previous dot com explosion? There were even movies about it!)

Read moreShow less

New Study Reveals Which Forces Are Driving Electric Vehicle Adoption

David Shultz

David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.

New Study Reveals Which Forces Are Driving Electric Vehicle Adoption
Photo by Jannes Glas on Unsplash

The state of California wants 100% of new passenger vehicles sales to be fully electric by 2035. Last year, the state hit a nation-leading 16%. That’s pretty good, but 84% is still a long way to go.

A new study, published Monday in Proceedings of the National Academy of Sciences, investigates which factors have been responsible for the rise in new EV sales nationally. The findings indicate that consumers are increasingly likely to choose an electric vehicle, and nearly all of the gains can be explained simply by improving technologies.

Read moreShow less

Colleen Wachob On Navigating Her Wellness Journey As An Entrepreneur

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

Colleen Wachob On Navigating Her Wellness Journey As An Entrepreneur
Courtesy of Behind Her Empire

On this episode of Behind Her Empire, mindbodygreen co-founder and co-CEO Colleen Wachob shares her perspective on managing stress and navigating self-worth as an entrepreneur and the importance of celebrating the wins in your business.

Read moreShow less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending